EBAC European Biotech Acquisition Corp

  1. Stocks
  2. Financial Services
  3. NASDAQ: EBAC

Price (delayed)

$11.19

Market cap

$183.5M

P/E Ratio

559.5

Dividend/share

N/A

EPS

$0.02

Enterprise value

$183.19M

Highlights
The quick ratio has soared by 95% from the previous quarter but it has plunged by 77% YoY
EBAC's price to earnings (P/E) is 151% more than its last 4 quarters average of 223.2
The company's EPS has shrunk by 82% YoY and by 50% QoQ
Sector: Financial Services
Industry: Shell Companies
Peers: OCSL OFS

Key stats

What are the main financial stats of EBAC
Market
Shares outstanding
16.4M
Market cap
$183.5M
Enterprise value
$183.19M
Valuations
Price to earnings (P/E)
559.5
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
534.25
EV/EBITDA
534.25
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
$342,895
EBITDA
$342,895
Free cash flow
-$514,792
Per share
EPS
$0.02
Free cash flow per share
-$0.03
Book value per share
-$0.49
Revenue per share
$0
TBVPS
$7.91
Balance sheet
Total assets
$129.75M
Total liabilities
$8.55M
Debt
$0
Equity
-$8.06M
Working capital
-$438,931
Liquidity
Debt to equity
0
Current ratio
0.45
Quick ratio
0.39
Net debt/EBITDA
-0.9
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
0.3%
Return on equity
N/A
Return on invested capital
0.3%
Return on capital employed
0.3%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

EBAC stock price

How has the European Biotech Acquisition stock price performed over time
Intraday
-4.44%
1 week
13.6%
1 month
10.14%
1 year
15.01%
YTD
10.79%
QTD
10.79%

Financial performance

How have European Biotech Acquisition's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$2.82M
Net income
$342,895
Gross margin
N/A
Net margin
N/A
The operating income has plunged by 156% YoY and by 29% from the previous quarter
European Biotech Acquisition's net income has shrunk by 77% YoY and by 60% QoQ

Growth

What is European Biotech Acquisition's growth rate over time

Valuation

What is European Biotech Acquisition stock price valuation
P/E
559.5
P/B
N/A
P/S
N/A
EV/EBIT
534.25
EV/EBITDA
534.25
EV/Sales
N/A
EBAC's price to earnings (P/E) is 151% more than its last 4 quarters average of 223.2
The company's EPS has shrunk by 82% YoY and by 50% QoQ
EBAC's equity is down by 33% since the previous quarter and by 21% year-on-year

Efficiency

How efficient is European Biotech Acquisition business performance
The ROA has plunged by 75% YoY and by 57% from the previous quarter
The return on invested capital has dropped by 75% year-on-year and by 57% since the previous quarter

Dividends

What is EBAC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for EBAC.

Financial health

How did European Biotech Acquisition financials performed over time
The quick ratio has soared by 95% from the previous quarter but it has plunged by 77% YoY
The company's current ratio has shrunk by 75% YoY but it has surged by 61% QoQ
EBAC's debt is 100% more than its equity
EBAC's equity is down by 33% since the previous quarter and by 21% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.